ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements with these filters
Promoter Uma Devi Chigurupati acquired 2.48 crore shares of Granules India Ltd via the open market. This transaction increases the promoter stake by 8.70%.
The company submitted its quarterly shareholding pattern disclosure as required by SEBI regulations for the period ended September 16, 2026.
Granules India allotted 2.49 crore equity shares to its promoter group upon warrant conversion, raising Rs. 1,461.50 Crore. This increases the company's total paid-up equity capital.
Granules India received Rs. 1,093 crore from the Promoter group, representing the balance 75% subscription for the conversion of 2.49 crore warrants into equity shares.
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares of Granules India Ltd via block deal and open market, reducing aggregate promoter stake.
Granules India Q1 FY27 results show strong performance with Revenue growing 22% YoY and PAT up 60%, driven by a significant mix shift towards high-margin Complex Generics.
Granules India Limited announced the internal transfer of Mr. Sanjay Kumar, Chief Strategy Officer, to its subsidiary Ascelis Peptides Private Limited as CEO.
Granules India Limited held its 35th Annual General Meeting on August 06, 2026. Shareholders adopted financial statements, approved a final dividend, and reappointed a director.
Life Insurance Corporation of India sold 49,56,124 equity shares of Granules India Ltd via market sale. LIC's stake reduced from 5.020% to 2.916%.
Granules India delivered record Q1 results, pivoting from volume-driven to a higher-margin complex generic and peptide-led platform. Profitability grew 60% YoY despite regulatory headwinds at Gagillapur, highlighting strong execution and diversification into regulated markets.
Granules India Ltd submitted a Monitoring Agency report for the quarter ended June 30, 2026. The report tracks proceeds from a Preferential Issue.
Granules India delivered a strong Q1FY27 with 22% YoY revenue growth and 60% PAT growth, driven by a portfolio shift toward high-margin Complex Generics.
Granules India reported Q1 FY27 revenue of ₹1,476.8 Crore, up 22% YoY. PAT grew 60% YoY to reach ₹180 Crore.
Granules India Ltd reported revenue from operations of ₹1,477 Cr (+22.0% YoY) and net profit of ₹180 Cr (+59.9% YoY) for Q1 FY27.
Granules India Limited released its Business Responsibility & Sustainability Report for FY 2025-26. The report highlights achievements in ESG, climate action, and workplace safety certifications.
Granules India convened its 35th AGM for August 06, 2026. Agenda includes adopting FY26 financials and approving a Rs.1.75 per share final dividend.
Granules India Limited submitted its Integrated Annual Report for FY 2025-26. The 35th AGM is scheduled for August 06, 2026, via video conferencing.
Granules India Ltd will hold a board meeting on 21 July 2026 to approve its unaudited Q1 results. Insider trading window remains closed till 23 July 2026.
Granules India secured Sole First-to-File ANDA status for Sodium Oxybate Extended-Release. This milestone strengthens its complex generics portfolio in the US market.
Granules India reported Q3FY26 revenue of ₹13,879 Mn (up 22% YoY) and PAT of ₹1,502 Mn (up 28% YoY), driven by Finished Dosage growth in North America and Europe.
Granules India's US subsidiary received a USFDA EIR with VAI classification for its Chantilly facility. The report concludes a March 2026 inspection involving four observations.
Granules India reported Q3FY26 revenue of ₹13,879 Mn with a 22% YoY growth. Strategy focuses on shifting from integrated to complex generics, supported by R&D and US portfolio expansion.
Granules India clarified that recent trading volume spurts are purely market-driven. The company confirmed compliance with all SEBI price-sensitive disclosure requirements.
Granules India delivered record performance in FY26, crossing INR 5,000 Cr revenue with 65% gross margins. Management focused on complex generics and the successful integration of Senn Chemicals' peptide business.
Granules India delivered a strong Q3FY26 with 22% YoY revenue growth, despite a temporary EBITDA loss in its Acyl-S peptide CDMO business. Operating performance improved on execution and leverage.
Granules India Limited has assigned Mr. Harsha Chigurupati, currently an Executive Director, the additional charge of Head of Transformation & Information Technology. The change is effective from April 30, 2026, following board approval. This move reflects a leadership expansion within the company's senior management team.
Granules India Limited has recommended a final dividend of Rs 1.75 per equity share for the financial year 2025-26. The record date is set for July 30, 2026, with the dividend payment expected to be completed by September 4, 2026, subject to shareholder approval at the upcoming General Meeting.
Granules India Limited has fixed July 30, 2026, as the record date to determine shareholders eligible for the final dividend for the financial year ended March 31, 2026. This announcement follows SEBI listing regulations and provides timeline clarity for investors.
Granules India Limited filed its Monitoring Agency Report for the quarter ended March 31, 2026. The company has received ₹665.63 Crore from a preferential issue of equity shares and warrants. India Ratings & Research confirmed there are no deviations from the stated objects of the issue.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Generics and Peptide CDMO.